Cargando…

Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study

BACKGROUND: Critically ill patients lose up to 2% of muscle mass per day. We assessed the feasibility of administering a leucine-enriched essential amino acid (L-EAA) supplement to mechanically ventilated trauma patients with the aim of assessing the effect on skeletal muscle mass and function. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Wandrag, L., Brett, S. J., Frost, G. S., To, M., Loubo, E. Alves, Jackson, N. C., Umpleby, A. M., Bountziouka, V., Hickson, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737604/
https://www.ncbi.nlm.nih.gov/pubmed/31511044
http://dx.doi.org/10.1186/s13063-019-3639-2
_version_ 1783450686662377472
author Wandrag, L.
Brett, S. J.
Frost, G. S.
To, M.
Loubo, E. Alves
Jackson, N. C.
Umpleby, A. M.
Bountziouka, V.
Hickson, M.
author_facet Wandrag, L.
Brett, S. J.
Frost, G. S.
To, M.
Loubo, E. Alves
Jackson, N. C.
Umpleby, A. M.
Bountziouka, V.
Hickson, M.
author_sort Wandrag, L.
collection PubMed
description BACKGROUND: Critically ill patients lose up to 2% of muscle mass per day. We assessed the feasibility of administering a leucine-enriched essential amino acid (L-EAA) supplement to mechanically ventilated trauma patients with the aim of assessing the effect on skeletal muscle mass and function. METHODS: A randomised feasibility study was performed over six months in intensive care (ICU). Patients received 5 g L-EAA five times per day in addition to standard feed (L-EAA group) or standard feed only (control group) for up to 14 days. C-reactive protein, albumin, IL-6, IL-10, urinary 3-MH, nitrogen balance, protein turnover ([1-13C] leucine infusion), muscle depth change (ultrasound), functional change (Katz and Barthel indices) and muscle strength Medical Research Council (MRC) sum score to assess ICU Acquired Weakness were measured sequentially. RESULTS: Eight patients (9.5% of screened patients) were recruited over six months. L-EAA doses were provided on 91/124 (73%) occasions. Inflammatory and urinary marker data were collected; serial muscle depth measurements were lacking due to short length of stay. Protein turnover studies were performed on five occasions. MRC sum score could not be performed as patients were not able to respond to the screening questions. The Katz and Barthel indices did not change. L-EAA delivery was achievable, but meaningful functional and muscle mass outcome measures require careful consideration in the design of a future randomised controlled trial. CONCLUSION: L-EAA was practical to provide, but we found significant barriers to recruitment and measurement of the chosen outcomes which would need to be addressed in the design of a future, large randomised controlled trial. TRIAL REGISTRATION: ISRCTN Registry, ISRCTN79066838. Registered on 25 July 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3639-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6737604
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67376042019-09-16 Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study Wandrag, L. Brett, S. J. Frost, G. S. To, M. Loubo, E. Alves Jackson, N. C. Umpleby, A. M. Bountziouka, V. Hickson, M. Trials Research BACKGROUND: Critically ill patients lose up to 2% of muscle mass per day. We assessed the feasibility of administering a leucine-enriched essential amino acid (L-EAA) supplement to mechanically ventilated trauma patients with the aim of assessing the effect on skeletal muscle mass and function. METHODS: A randomised feasibility study was performed over six months in intensive care (ICU). Patients received 5 g L-EAA five times per day in addition to standard feed (L-EAA group) or standard feed only (control group) for up to 14 days. C-reactive protein, albumin, IL-6, IL-10, urinary 3-MH, nitrogen balance, protein turnover ([1-13C] leucine infusion), muscle depth change (ultrasound), functional change (Katz and Barthel indices) and muscle strength Medical Research Council (MRC) sum score to assess ICU Acquired Weakness were measured sequentially. RESULTS: Eight patients (9.5% of screened patients) were recruited over six months. L-EAA doses were provided on 91/124 (73%) occasions. Inflammatory and urinary marker data were collected; serial muscle depth measurements were lacking due to short length of stay. Protein turnover studies were performed on five occasions. MRC sum score could not be performed as patients were not able to respond to the screening questions. The Katz and Barthel indices did not change. L-EAA delivery was achievable, but meaningful functional and muscle mass outcome measures require careful consideration in the design of a future randomised controlled trial. CONCLUSION: L-EAA was practical to provide, but we found significant barriers to recruitment and measurement of the chosen outcomes which would need to be addressed in the design of a future, large randomised controlled trial. TRIAL REGISTRATION: ISRCTN Registry, ISRCTN79066838. Registered on 25 July 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3639-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-09-11 /pmc/articles/PMC6737604/ /pubmed/31511044 http://dx.doi.org/10.1186/s13063-019-3639-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wandrag, L.
Brett, S. J.
Frost, G. S.
To, M.
Loubo, E. Alves
Jackson, N. C.
Umpleby, A. M.
Bountziouka, V.
Hickson, M.
Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study
title Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study
title_full Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study
title_fullStr Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study
title_full_unstemmed Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study
title_short Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study
title_sort leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737604/
https://www.ncbi.nlm.nih.gov/pubmed/31511044
http://dx.doi.org/10.1186/s13063-019-3639-2
work_keys_str_mv AT wandragl leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy
AT brettsj leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy
AT frostgs leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy
AT tom leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy
AT louboealves leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy
AT jacksonnc leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy
AT umplebyam leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy
AT bountzioukav leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy
AT hicksonm leucineenrichedessentialaminoacidsupplementationinmechanicallyventilatedtraumapatientsafeasibilitystudy